Answers are grounded in this paper and cite their sources.
Type 1 and Type 2 diabetes, despite fundamentally different etiologies, lead to remarkably similar microvascular and macrovascular complications. This shared phenotype is not fully explained by hyperglycemia alone or by differences in insulin exposure. We propose that, at the vascular level, a common state of selective vascular insulin resistance characterized by impaired PI3K/Akt-mediated vasoprotective signaling with relative preservation of MAPK-mediated pro-inflammatory and vasoconstrictive signaling may contribute to these shared vascular outcomes. This Perspective advances a hypothesis-generating conceptual framework intended to integrate existing mechanistic and clinical observations rather than establish a definitive causal model. Prior work has defined selective insulin resistance at the cellular level; here, we propose extending this concept to a disease-level framework that may explain the parallel development of complications in both forms of diabetes. In Type 2 diabetes, metabolic insulin resistance drives this imbalance in the setting of compensatory hyperinsulinemia, whereas in Type 1 diabetes, nonphysiologic peripheral insulin delivery combined with metabolic stress may promote a comparable signaling disturbance. This review synthesizes mechanistic and clinical observations into a unified, testable hypothesis and outlines potential avenues for validation. Rather than replacing established glucotoxic mechanisms, this model suggests that impaired insulin signaling may modify tissue susceptibility to metabolic injury and offers a framework for evaluating therapies aimed at restoring physiologic vascular insulin action.
No takes yet. Share an insight, caveat, or question.
Gabbay et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: